Multimodality Therapy (docetaxel, sunitinib, and external beam radiotherapy) for Recurrent High Risk Prostate Cancer- A Phase II Study

Description:

This trial seeks to determine whether multiple therapies, including chemotherapy, earlier in the disease will result in longer periods of progression-free survival (PSA progression and metastases). Eligibility includes:   radical prostatectomy within  3 yrs; Gleason score 7-10; PSA = 2.0 ng/ml and = 0.2 ng/ml; rising PSA without evidence of metastatic disease; NO prior systemic or biologic therapy.

Link:

http://clinicaltrials.gov/ct2/show/NCT00734851

Site:

Johns Hopkins Hospital

Principal Investigator:

Phuoc Tran, M.D.